Unknown

Dataset Information

0

Treatment of refractory dry eye associated with graft versus host disease with 0.03% tacrolimus eyedrops.


ABSTRACT:

Purpose

We investigate the efficacy of 0.03% topical tacrolimus eyedrops for the treatment of dry eye in graft versus host disease (GVHD) patients resistant/intolerant to 0.05% topical cyclosporine.

Methods

Forty-three patients were enrolled in this prospective study. After completing a 1-year run-in period of using artificial tears, 50% autologous serum eyedrops, and punctal plug occlusion, all the symptomatic patients (n=29) were treated with 0.05% topical cyclosporine (Restasis(®); Allergan, Inc.). After 1 month, the patients who presented topical or systemic intolerance to cyclosporine were instructed to instill 0.03% topical tacrolimus once a day for 3 months (n=14). All the patients were allowed to continue with their basal dry eye treatment. Visual acuity, fluorescein staining, Schirmer test, fluorescein tear break-up time, and tear meniscus height measurement were evaluated fortnightly (minimum 3 months). Subjective assessments of symptoms were also reported at the beginning and at the end of the study.

Results

Dry eye symptoms and signs improved statistically (P<0.05) and significantly with tacrolimus and cyclosporine topical treatment. No significant differences were observed between both the groups. The mean follow-up time was 12.14±2.69 months (range 10-18 months).

Conclusion

The findings of this prospective pilot study suggest that cyclosporine-intolerant patients with dry eye associated with GVHD can be effectively treated with topical tacrolimus.

SUBMITTER: Sanz-Marco E 

PROVIDER: S-EPMC3787325 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Treatment of refractory dry eye associated with graft versus host disease with 0.03% tacrolimus eyedrops.

Sanz-Marco Empar E   Udaondo Patricia P   García-Delpech Salvador S   Vazquez Amparo A   Diaz-Llopis Manuel M  

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20130815 8


<h4>Purpose</h4>We investigate the efficacy of 0.03% topical tacrolimus eyedrops for the treatment of dry eye in graft versus host disease (GVHD) patients resistant/intolerant to 0.05% topical cyclosporine.<h4>Methods</h4>Forty-three patients were enrolled in this prospective study. After completing a 1-year run-in period of using artificial tears, 50% autologous serum eyedrops, and punctal plug occlusion, all the symptomatic patients (n=29) were treated with 0.05% topical cyclosporine (Restasis  ...[more]

Similar Datasets

| S-EPMC3519994 | biostudies-literature
| S-EPMC3716013 | biostudies-literature
| S-EPMC10648694 | biostudies-literature
| S-EPMC9562362 | biostudies-literature
| S-EPMC7192843 | biostudies-literature
| S-EPMC7378454 | biostudies-literature
| S-EPMC6102256 | biostudies-other
| S-EPMC8780105 | biostudies-literature
2023-12-19 | PXD012036 | Pride
| S-EPMC9981701 | biostudies-literature